Achievement of Robust Preclinical Milestones Underscores the Potential of DPX-NEO as a Crucial Enabling Agent in Developing Personalized Neoepitope-based Cancer Treatments HALIFAX, Nova Scotia , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX:IMV)

Data From First Dosing Cohort Show a 70% Disease Control Rate – Including 30% of Patients with Partial Responses – and Demonstrate a Tolerable Safety Profile Immunovaccine to Host a Conference Call to Review the Results on Tuesday, December 5, 2017 at 8:00 am ET HALIFAX, Nova Scotia , Dec.

HALIFAX, Nova Scotia , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it will hold a webcast and conference call tomorrow ( Tuesday, December 5, 2017 ) at 8:00 a.m. ET .

Following Successful Achievement of Preclinical Milestones, USAID-backed Malaria Vaccine Program Will Advance Toward Clinical Stage Development HALIFAX, Nova Scotia , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immunotherapy and vaccine company,

Company Also Presents Poster Highlighting Preclinical Research on Combination Immunotherapies at SITC 2017 HALIFAX, Nova Scotia , Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that the Society for

HALIFAX, Nova Scotia , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today released its financial and operational results for the third quarter ended September 30 , 2017.    “We have had another successful quarter at

HALIFAX, Nova Scotia , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage vaccine and immuno-oncology company, today announced that Health Canada has granted Sunnybrook Research Institute regulatory clearance to begin recruiting patients for its Phase 2

HALIFAX, Nova Scotia , Oct. 17, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it has received a two-year extension of the maturity of its Province of Nova Scotia loan authorized in 2013.

Presentation at the 2017 SITC Meeting Will Highlight Preclinical Research on Predicting the Efficacy of Novel Combination Immunotherapies Researchers at the ReSViNET Conference Will Present Data Focused on Immunovaccine’s Novel RSV Target HALIFAX, Nova Scotia , Oct.

HALIFAX, Nova Scotia , Sept. 29, 2017 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced   Chief Executive Officer Frederic Ors  is scheduled to present an overview of the Company’s recent progress and future strategy at two